Watch PTGX. Know when insiders buy.
One email the day a filing lands. Free.
PTGX
Protagonist Therapeutics, Inc
145.16
+0.07 +0.05%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
34
FLAG · insiders 25, shorts 42
Insiders, 90 days
−$18.2M
net selling · 0 buys, 3 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
2 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $9.4BP/E 142.3DIV YIELD —FCF YIELD 1.39%REV TTM —NET INCOME $82.9M +59.3%NET CASH $410.2M52W 58.38 – 158.62SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $213.5M | +3749.2% | — | $158.8M | $162.8M | — | 2.29 | $219.1M | $168K | $218.9M | Aug 5 |
| Q1 2026 · Mar 31 | — | — | — | −$3.6M | $3.8M | — | 0.05 | −$48.9M | $215K | −$49.2M | May 5 |
| Q4 2025 · Dec 31derived | — | — | — | −$50.4M | −$44.4M | −133.7% | -0.70 | −$37M | $144K | −$37.1M | Feb 25 |
| Q3 2025 · Sep 30 | — | — | — | −$46.4M | −$39.3M | — | -0.62 | −$1.9M | $88K | −$2M | Nov 6 |
| Q2 2025 · Jun 30 | $5.5M | — | — | −$42M | −$34.8M | — | -0.55 | −$28.8M | $813K | −$29.6M | Aug 5 |
| Q1 2025 · Mar 31 | — | — | — | −$19.3M | −$11.7M | −105.6% | -0.19 | $125.4M | $545K | $124.8M | May 5 |
| Q4 2024 · Dec 31derived | — | — | — | $126.8M | $131.7M | +381.7% | 2.01 | −$29.2M | $310K | −$29.5M | Feb 25 |
| Q3 2024 · Sep 30 | — | — | — | −$41.5M | −$33.2M | — | -0.54 | −$27.9M | $775K | −$28.6M | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$38.8M | −$30.6M | — | -0.50 | $268.6M | $28K | $268.6M | Aug 6 |
| Q1 2024 · Mar 31 | — | — | — | $206.3M | $207.3M | — | 3.26 | −$27.4M | $242K | −$27.7M | May 6 |
| Q4 2023 · Dec 31derived | — | — | — | $23M | $27.3M | — | 0.52 | $17M | $19K | $16.9M | Feb 25 |
| Q3 2023 · Sep 30 | — | — | — | −$38.3M | −$34.1M | — | -0.58 | −$26.6M | $404K | −$27M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$158.1M | −$130.1M | — | -2.05 | $57.7M | $1.6M | $56.1M | — | — |
| FY2024 · to Dec 31 | — | — | $252.8M | $275.2M | — | 4.23 | $184.2M | $1.4M | $182.8M | — | — |
| FY2023 · to Dec 31 | — | — | −$93.7M | −$79M | — | -1.39 | −$70.2M | $609K | −$70.8M | — | — |
| FY2022 · to Dec 31 | — | — | −$131.4M | −$127.4M | — | -2.60 | −$108.1M | $795K | −$108.9M | — | — |
| FY2021 · to Dec 31 | — | — | −$125.8M | −$125.6M | — | -2.71 | −$107.9M | $1.1M | −$109M | — | — |
| FY2020 · to Dec 31 | — | — | −$64.5M | −$66.2M | — | -1.92 | −$72.5M | $471K | −$73M | — | — |
Every number comes from Protagonist Therapeutics, Inc's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.